The term "Primary Cutaneous B-Cell Lymphoma" (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature.
Introduction
The term "primary cutaneous B-cell lymphoma" (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells, which primarily involves the skin. In the late 1980s, cutaneous B-cell lymphoma (CBCL) were for the first time recognized as an autonomous clinical entity based on homogeneous clinical and prognostic characteristics, with an overall better disease course if compared with nodal counterparts. [1, 2] The absence of evident extracutaneous disease is a necessary condition for the diagnosis of PCBCL to be confirmed after 6-month follow-up to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement [2] that may have a completely different clinical behavior and prognosis.
Classification
Nowadays, long debate has been made about pathologic classification of PCBCL. Due to the different clinical behavior, the distinction of cutaneous lymphomas from nodal counterparts is mandatory to settle the optimal treatment, but it is a relatively recent achievement. In fact, both Revised European-American Classification of Lymphoid Neoplasms [3] and World Health Organization (WHO) [4] classifications for NHLs do not deal specifically with cutaneous lymphomas even if they can be adapted to include most of the entities primarily involving the skin. Applying the same terminology used in nodal lymphoma classification, the European Organisation for the Research and Treatment of Cancer (EORTC) proposed a new classification for primary cutaneous lymphomas. [5] Conversely, in 2001, the WHO proposed a unified system that referred to both extranodal (including primary cutaneous) and nodal lymphomas adopting a similar terminology. [6] The differences among original EORTC and WHO CBCL's classifications lead to confusion. [7] For example, many lesions classified as "follicle center cell lymphoma" in the original EORTC classification and may be classified as "diffuse large B-cell lymphoma" (DLBCL) in the WHO classification and, in contrast with their nodal counterpart, they exhibit clinically indolent behavior and respond to radiotherapy without need of systemic chemotherapy. [8] The definition of "large B-cell lymphoma of the leg" can easily show the intrinsic limits of the original EORTC classification. "Large B-cell lymphoma of the leg" was defined CBCL with preponderance of large B-cells arising in the lower extremities. Based on this criteria, histologically, identical lesions would be classified as "large B-cell lymphoma of the leg" if located on the lower extremities and "follicle center cell lymphoma" if located elsewhere. [8] In response to the need of a univocal and comprehensive classification solely devoted to primary cutaneous lymphoma, the WHO-EORTC published in 2005 the unified classification for primary cutaneous lymphoma. [9] These guidelines were incorporated into the revised 4 th WHO classification of tumors of hematopoietic and lymphoid tissues in 2008 using the framework for nodal lymphomas. [10] Under this classification, primary cutaneous lymphoma are divided into cutaneous T-cell and natural killer-cell lymphomas, CBCLs, and precursor hematologic neoplasm. The CBCLs are classified into primary cutaneous marginal zone B-cell lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous DLBCL (PCDLBCL), leg type (LT), and PCDLBCL, other. [9, 10] 
Epidemiology
PCBCLs represent up to 25%-29% of primary cutaneous lymphomas, [11] for which an estimated annual incidence of 0.5-1 new case/100,000 has been reported. [12, 13] Three of the main European works analyzing the occurrences of cutaneous lymphomas published in 1983, [14] 1984, [15] and 1997 [16] reported, respectively, a 25%, 32%, and 20.8% of B-cells lymphomas. In 1997, Willemze et al. [5] reported that B-cell lymphomas represent the 18.8% of diagnosis in 626 patients registered by the Dutch Cutaneous Lymphoma Working Group between 1986 and 1994. Zackheim et al. [12] reviewing data from three United States (US) institutions with active PCBCLs found a considerably lower (4.5%) relative frequency of PCBCL in the US. The first large population-based study focusing on cutaneous lymphoma in the USA [11] reported that CBCLs accounted for 29% (IR = 3.1/1,000,000 person-years) of the 3884 cutaneous lymphomas registered. In recent retrospective studies from Japan and Korea, [17, 18] lower rates of PCBCL were found when compared to those reported in Western countries. Thus, the etiology of cutaneous lymphoma subtypes remains largely unknown, comparison of incidence rates, and patterns for specific subtypes may elucidate important clues for future studies. [11] PCBCL are more common in male and, in contrast to cutaneous T-cell lymphoma, they are almost exclusively a disease of non-Hispanic White. [11] Consisting with previous reports, [19, 20] Bradford et al. [11] found that the rates of CBCL steadily rose with age. Chronic inflammation, DNA damage, and diminished immune surveillance that occur with older age may contribute to lymphoma development. [11] 
Primary Cutaneous Marginal Zone Lymphoma
Introduction PCMZL is defined by the 2008 WHO classification for hematopoietic and lymphoproliferative disorders [10] as an indolent B-cell lymphoma composed of small B-cells, lymphoplasmacytoid cells, and mature plasma cells. [9, 21] It is included in the group of extranodal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) lymphoma. [10, 22] However, it has been debated since its first descriptions if PCMZL really shares pathogenic mechanisms and biological similitudes with systemic MALT counterpart, or it has to be considered a completely distinct entity, based on evidence of different translocations, expression of class-switched immunoglobulins (Igs), chemokine receptors, association with infective triggers. [23, 24] Clinical appearance PCMZL presents as single or more often multifocal, asymptomatic, or slightly itchy lesions that tend to Table 2 enlarge slowly and may reach over 3 cm of diameter. They appear as erythemato-cyanotic papules or nodules with shiny surface and no desquamation, more frequently localized at the arms or trunk. Rarely, PCMZL may present as multiple erythematous Figure 1 papules localized symmetrically on the face and thus mimicking granulomatous rosacea (PCMZL agminate). Furthermore, in patients which show serological positivity to antiphospholipid antibodies classical lesions associated with anetodermic scar. [25] [26] [27] Histopathology PCMZL is characterized by nodular infiltration of dermis and subcutis Figure 2 by small lymphocytic cells, lymphoplasmacytoid cells, mature plasma cells, and reactive germinal centers with macrophages. [21, 28] The infiltrate could be intermingled with a reactive T-cell infiltrate, in some cases almost totally obscuring the neoplastic B-cells. It could also be observable a diffuse plasmacytoid differentiation. [29] At immunohistochemistry, tumor cells show positivity for CD20, CD79a, and BCL-2 but are negative for BCL-6; plasmocytes are monotypic for kappa or lambda.
Two subtypes of PCMZL have been described: [24] A more common subtype (class-switched) with perivascular and periadnexial nodular infiltrate of plasma cells expressing IgG, IgA, IgE, and many intermingled T-cells. There are reactive germinal centers which express IgD. Neoplastic cells lack CXCR3 expression. The other subtype is the nonclass-switched one, and it is characterized by larger nodular infiltrates of neoplastic B-cells expressing IGM and CXCR3, a receptor for interferon (IFN)-gamma induced chemokines (a feature shared with other MALT lymphomas) in half of the cases and lower number of reactive T-cells.
Histopathological differential diagnosis
The most difficult differential diagnosis is versus B-cell pseudolymphomas that are often a true challenge, both for the dermatologist and for pathologist. Multifocal lesions, recalcitrant and relapsing clinical course, and demonstration of predominance of K or L light chain or monoclonality (using JH and JK primers) suggest a diagnosis of PCMZL. However, cases of pseudolymphomas with multifocal presentation are described [30] and "pseudoclonality" in the presence of oligoclonal B-cell infiltrate is a common problem with clonality assessment. [31] Other important differential diagnosis is B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) which secondarily involves skin in about 2% of cases. [32] Cutaneous involvement by CLL/SLL may resemble closely PCMZL both clinically and histologically, but tumor cells express a distinct immunophenotype (CD20+, CD79a+, CD5+, CD23+, and CD43+). [33, 34] Other differential diagnosis is cutaneous infiltration by an extramedullary plasmacytoma, especially when dense dermal infiltrate shows plasma cells with monotypic Ig light chains. [10, 21] 
Prognosis and prognostic factors
Prognosis of PCMZL is excellent, with an overall survival estimated up to 99% at 5 years. [9, [35] [36] [37] [38] [39] Up to 50% of patients experience cutaneous relapses, locally or at a distance, but these do not impair prognosis. [40, 41] Extracutaneous spread is quite rare, observable in <10% of patients, especially in the nonclass-switched subtype. [24] Systemic spread is often preceded by large cell transformation and the demonstration of translocations t(14;18)(q32;q21) IgH/BCL-2 and t(14;18)(q32;q21) IgH/MALT1. [42] Histological transformation of low-grade B-cell lymphomas toward more aggressive forms is a well-known phenomenon and it represents an independent negative prognostic factor, leading to resistance to treatments and higher mortality rates. Blastic transformation (presence of up to 30% of large transformed cells in the infiltrate) is a rare event, especially in cutaneous MZL. Its correlation with a more aggressive behavior has been recently analyzed by Magro et al. [43] Therapy Due to Table 4 lack of randomized, controlled trials, treatment recommendations for PCMZL are based on small retrospective studies. Consensus recommendations have been published by the EORTC and International Society for Cutaneous Lymphoma (ISCL), [44] but in most cases, the best approach requires a multidisciplinary evaluation by dermatologist, medical oncologist, hematologist, and radiotherapist.
For single small lesion/multiple localized lesions, the recommended first-line treatments are radiotherapy or surgical excision. In selected cases with positive serology for chronic Borrelia burgdorferi infection, oral antibiotics (cephalosporins or tetracyclines classes) can be tried. As second line treatment in these cases, intralesional (IL) IFN-alpha (3 mil UI three times/week), IL rituximab (CR 71%), [45] and IL corticosteroid are all viable options.
In multifocal disease, local radiotherapy, intravenous rituximab, oral antibiotics (if B. burgdorferi positive), oral chlorambucil are all well-tolerated and safe options. [46] Second-line treatments include IL IFN-alpha, IL rituximab, topical or IL steroids.
In all cases, a wait-and-see strategy, reserving active treatments only to symptomatic lesions, is a feasible option.
Primary Cutaneous Follicle Center Lymphoma
Introduction PCFCL represents about the 11%-18% [9, 47] of all cutaneous lymphomas and is the most common variant of PCBCL representing approximately the 55% of all CBCLs. [10] It is described as a separate entity in the WHO-EORTC classification of primary cutaneous lymphomas [9] as well as in the new WHO classification of hematopoietic and lymphoid tissue tumors. [10] Clinical appearance PCFCL usually presents as solitary or Table 2 grouped plaques, nodules, or tumors. Presentation with multifocal skin lesion is rarer and it is not associated with a more unfavorable prognosis. [9, 19, 48] Lesions are typically red to violet and have a smooth shiny mamillated surface. [49] The presence of erythematous papules and slightly indurated plaques surrounding tumor is a characteristic finding. In some cases, these lesions precede the development of tumor for months or even many years. The term of "reticulohistiocytoma of the dorsum" or "Crosti lymphoma" was used to describe the typical presentation of the PCFCL on back. [50] Less typical presentation may represent a diagnostic challenge. In literature, they are described cases of PCFCL presenting as miliary papules and pustules on the face and forehead, difficult to differentiate from the most common face dermatosis (rosacea, folliculitis, acne, lupus miliaris). [51, 52] Rosacea-like presentation of PCFCL may include the presence of infiltrative lesions of the nose or rhinophyma. [27, 53] Scalp localization may mimic other causes of scarring alopecia by presenting as cluster of tumid annular erythematous plaques. [54] Differential diagnoses include inflammatory lesions (e.g., acne cysts and epidermal inclusion cysts), arthropod bites, other cutaneous neoplasms (basal cell carcinoma, Merkel cell carcinoma, cutaneous lymphoid hyperplasia), and other non-B-cell cutaneous lymphomas (e.g., CD8 cutaneous lymphoma of the ear, CD4 pleomorphic small, medium T-cell lymphoma, or folliculotropic mycosis fungoides). [55] Histopathology PCFCL exhibits dermic and subcutaneous infiltrates composed of neoplastic follicle center cells that almost constantly spare the epidermis. Neoplastic follicle center cells usually are a mixture of centrocytes (small/medium and large cleaved and often multilobulated follicular center cells) and variable numbers of centroblasts (large noncleaved follicular center cells with prominent nucleoli).
Architectural pattern is variable along a continuum from follicular, nodular, diffuse growth patterns and a combination thereof. Age, growth rate, and location of biopsied lesions influenced the framework of histological presentation. [9, 12, 49, 56] Small and early lesions contain a mixture of centrocytes, relatively few centroblasts, and many reactive T-cells. Early infiltrates may have a patchy perivascular and periadnexal growth pattern, a common diagnostic pitfall of a reactive infiltrate or "pseudolymphoma." [57] [58] [59] With the progression of lesions to tumor, neoplastic B-cells increase in both number and size whereas the number of reactive T-cells steadily decreases. [9, 49, 60] The typical follicular growth pattern is more frequently observed on scalp lesions than in those arising on the trunk. [56] The abnormal follicles are composed of malignant BCL-6 follicle center cells enmeshed in a network of CD21 or CD35 follicular dendritic cells. The follicles are ill-defined mantle zone that is frequently reduced or absent and lacks on tingible body macrophages. [56, 61] In tumorous skin lesions, follicular structures are no longer visible, except for occasional scattered CD21 or CD35 follicular dendritic cells. Generally, a monotonous population of large centrocytes and multilobulated cells, and in rare cases, spindle-shaped cells, with a variable admixture of centroblasts and immunoblasts is present. [49, 50, 52, 61] The follicle center cells express a CD20+, CD79a+, BCL-6+, BCL-2− immunophenotype and a monotypic staining for surface Igs (commonly undetectable in tumorous lesions). Clonally rearranged Ig genes are usually demonstrable as the presence of somatic hypermutation of variable heavy and light chain genes. [62] The expression of CD43 and CD10 is variable 64, 65. A positivity for the CD10 is predominantly observed in PCFCL with follicular growth pattern and uncommonly in the diffuse one. [63, 64] Immunostaining for multiple myeloma-1/IFN-regulatory factor-4 (MUM1/IRF4) and Forkhead box P1 (FOX-P1) is negative in the majority of cases, [65] and their rare positivity does not seem to influence the prognosis. [66] PCFCLs do not show the BCL-2 protein and its locus containing t(14;18) translocation, which is distinctive of systemic follicular lymphomas and a fraction of systemic DLBCL LT. [60, 67, 68, 69] 
Prognosis and predictive factors
The prognosis of PCFCLs is always excellent with a 5-year survival of >95% in large studies. [2, 5, 19, 49, 50, 56, 60] PCFCL is an indolent disease, even if left untreated, skin lesions may be stable, gradually increase in size over years, or regress in rare cases. Dissemination to extracutaneous sites remains an exceptional event (it occurs in 5%-10% of cases). [54] As reported by Zinzani et al. in one of the largest series published in literature, [70] recurrence after therapy is common (up to 46.5% of cases), it is usually confined to the skin, and it does not affect prognosis. Although the higher incidence of relapse was observed in the first 4 years, a constant 2% to 6% risk of relapse was noted beyond 10 years. [70] The growth pattern (follicular or diffuse), number of blast cells, likewise the presence of multifocal skin disease, do not seem to influence prognosis. [9, 19, 48] In contrast, site of presentation is suggested to influence prognosis: PCFCL presenting on the leg carries a poorer prognosis, with 5-year disease specific survival reported at 41%. [71] There are instances of PCFCL either progressing or coexisting with DLBCL. [66] Transformation to high-grade lymphoma is an independent negative prognostic factor.
Therapy
Local radiation Table 4 therapy with a dose of at least 30 Gy and a margin of clinically uninvolved skin of at least 1-1.5 cm is the treatment of choice in patients presenting with solitary or localized skin lesions. [44] Surgical excision is a reasonable option for small, well-demarcated, solitary lesions. No details are provided concerning excision margins. [44] Surgery appears to be an equally effective treatment option for PCBCL, while avoiding some local complications associated with radiation therapy. [72] Patients with indolent, few scattered lesions of PCFCL may be treated by radiotherapy of all visible skin lesions. Alternatively, a wait-and-see policy associated with treatment of only symptomatic skin lesions is considered acceptable for initial management. IL treatment with IFN-alpha (all the seven cases described in literature obtained a complete response) or rituximab (10 of the 12 patients treated reached a complete response and 2 patients reached a partial response) [46] are proposable second-line choices. [44] Topical therapies such as high-potency steroids, imiquimod, nitrogen mustard, and bexarotene and IL steroids [73] seem to have some success in selected, symptomatic patients. [44, 74] Similar approach can be adopted to treat relapses that occur in approximately 30% of patients and does not affected prognosis. [44, 46] In patients with very extensive skin lesions, particularly where local treatment is not effective or desirable, systemic rituximab (375 mg/m 2 weekly for 1-8 week) can be purposed. [44] Combination chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone [R-CHOP] or rituximab, cyclophosphamide, vincristine, and prednisolone) should be reserved for the exceptional cases of patients with resistant, relapsing, or progressive disseminated skin lesion or large tumors or extracutaneous disease. [44, 75] Introduction PCDLBCL, LT is an aggressive type of CBCL, characterized by skin lesions mainly on the legs and a predominance of diffuse sheets of centroblasts and immunoblasts. [9] PCDLBCL, LT was first reported as a subgroup of PCFCL in 1987 based on its particular histological feature and more aggressive behavior. [60] In 1996, Vermeer et al. proposed the term "primary cutaneous large B-cell lymphoma of the leg," which was used to classify it as a distinctive subgroup in the EORTC classification. [5] In the last WHO-EORTC classification, this entity was finally defined PCDLBCL, LT to reflect the predominant but not exclusive anatomic location of the lesions. In this classification, PCDLBCL, LT was distinguished from other CBCL which may present large B-cells: PCFCL and PCDLBCL, other a group of rare large B-cell lymphomas. [9, 76] PCDLBCL, LT represents 5%-10% of all PCBCLs commonly presenting in elderly females (male:female 1:3-4), with a peak incidence in the seventh decade of life. [77] Clinical appearance Patients present solitary or multiple Table 2 , rapidly growing, red to bluish-red firm tumors on one or both legs, usually below the knee [ Figure 3a ]. In 10%-15% of cases, the lesions are localized at other sites such as the trunk, head-neck, and upper arms.[ Figure 3b ] Multiple lesions may be disseminated or aggregated [ Figure 5 ]. [9, 70, 77] Extracutaneous spreading is often reported, most commonly in lymph nodes, bone marrow, and nervous system. [78] Histopathology Histologically, there is a diffuse and dense infiltrate throughout the dermis that often involves the subcutis but is separated from the epidermis by a Grenz zone [ Figure 6 ]. The infiltrate mainly consists of confluent sheets of large B-cells with roundish nuclei, prominent nucleoli, and open chromatin resembling centroblasts and immunoblasts [ Figure 4 ].
The morphology of these cells is different from the cleaved and irregular nuclear morphology of the large centrocytes typically present in the infiltrate of PCFCL. Anaplastic cells are occasionally seen. Mitotic figures are frequently observed. T-cells are rare. [19, [77] [78] [79] [80] Tumor cells express B-cell markers (CD20, CD79a, and PAX5) and possible monotypic, surface, and cytoplasmic, Ig. In particular, cytoplasmic IgM expression seems to be a sensitive marker of PCDLBCL, LT as it is negative in PCFCL. [81] BCL-2, MUM1/IRF4, and FOX-P1 are strongly expressed in PCDLBCL, LT regardless of the location of the skin lesions, but not expressed in PCFCL. This immunophenotype is useful for the diagnosis of PCDLBCL, LT even if 10% of cases are negative for BCL-2 and MUM1/ IRF4. [76, 78, 82] BCL-2 overexpression is associated with a chromosomal amplification of BCL-2 gene in some cases, but t (14;8) is usually not found. [83, 84] PCDLBCL, LT is usually characterized by a high proliferation rate (>70%) and BCL-6, CD5, CD10, CD30, CD138, and cyclin D1 negativity [77] [ Figure 6c and d].
Cytogenetic studies have revealed a frequent inactivation of p15(INK4b) and p16(INK4a) as a result of promoter hypermethylation (respectively, 11% and 44% of all PCDLBCLs) [85] and chromosomal imbalances in up to 85% of PCDLBCL, LT (mainly gains of chromosome 2q, 3, 7p, 12q, 18q and losses of 6q, 13,14,17p, 19) . [9, 84, 86, 87] Translocations of myc, BCL-6, and IgH genes have been demonstrated by fluorescence in situ hybridization in PCDLBCL, LT but not PCFCL. [88] One gene expression study has revealed an activated B-cell profile in PCDLBCL, LT. [65] 
Prognosis and prognostic factor
The prognosis of PCDLBCL, LT is poor and characterized by frequent relapses and extracutaneous spreading. The 5-year survival rate is 40%-55%. [55, 79, 81] Higher survival rates have been reported by Zinzani et al. [70] and Kodama et al. [76] (61.7%). A location on the leg is a well-known negative prognostic factor, characterizing PCDLBCL, LT [19, 79, 83, 106] and, in addition, a large multicenter French study found that multiple skin lesions were also negative prognostic factors. [81] The presence of round cell morphology also correlates with a short survival. [19] Other factors that have been reported to be linked to a worse prognosis are the high expression of MUM1 and FOX-P1, and, as in other aggressive lymphomas, deletion of the CDKN2A locus on chromosome 9p21. [71, 76] Expression of Contd... [89] [90] [91] [92] [93] It can affect every organ.
Cutaneous manifestations are protean: they can present as livedo racemosa, panniculitis, or with painful nodules.
Large B cells with large cytoplasm and chromatine dense nuclei, localized inside small dermal and subcutaneous vessels. Tumour cells are CD20+and bcl2+, CD5+/-and/or CD10+/-Poor EBV-positive DLBCL of the elderly (EBV+ DLBCL-e) [94] [95] [96] EBV-positive large B cell lymphoma in patients older than 50 years without any personal history of immunodeficiency or previous lymphomas.
Commonest localizations of disease are skin, lung, stomach and tonsil.
Diffuse infiltrate composed by large immunoblast-like and plasmablast-like cells, associated with necrosis and macrophages. The tumour cells are CD20+, CD79a+, Pax-5+, MUM-1/IRF4+and bcl6-, CD10-, and can be CD30+. EBER is usually positive Poor Plasmoblastic Lymphoma (PBL) [97] Rare variant of DLBCL , EBV associated.
It affects chronically immunodeficient patients (AIDS and transplant recipients)
It mostly affects oral cavity.
Cutaneous involvement is characterized by solitary or multiple indolent skin coloured to cyanotic papules and nodules on trunk and limbs that can grow up to over 10 cm of diameter. The lesions may tend to ulcerate.
Diffuse or multinodular infiltration of tumour cells with immunoblast-like morphology or atypical plasmacytic appearance. Mitotic figures are numerous and atypical. Neoplastic cells shows a phenotype of plasma cell, CD38+, CD138+, VS38c+, and are CD20-and Pax-5-. May show variable positivity for CD10, CD79a, CD30, CD56. EBER is usually positive Poor Posttransplant lymphoprolifer-ative disorder (PTLD) [10, 98] Spectrum of lymphoid diseases, usually EBV driven.
From reactive and polyclonal B cells proliferations to true monomorphic neoplasms, indistinguishable from their counterparts occurring in immunocompetent individuals
Good Lymphomatoid Granulomatosis (LG) [99] [100] [101] [102] [103] [104] Angiocentric and angiodestructive EBV-associated B-cell lymphoproliferative disorder, involving almost in 100% cases lungs, but also skin, central nervous system and kidneys are common localization. Cutaneous manifestations (30% of cases at diagnosis) may vary from erythematous papules to subcutaneous nodules that can ulcerate or become necrotic, indurated plaques and macular rash, sometimes associated with facial oedema angiocentric and angiodestructive infiltrate composed by lymphocytes with admixed hystiocites, plasmacells and in a minority of cases, neutrophils and eosinophils. There is a predominance of small angiotropic CD4+lymphocytes, but a variable quote of atypical CD20+B cell is always present.
Poor EBV-positive mucocutaneous ulcer (EBVMCU) [105] Usually single, sharply delimited ulceration located commonly in the oropharynx, in the skin, or in the gastrointestinal tract. Frequently correlates with chronic immunosuppression Well delimited and superficial ulceration, with an underlying infiltrate composed by lymphocyte and immunoblasts, and a variable number of scattered eosinophils, plasmacells, histiocytes, and large blasts Hodgkin and Reed Sternberg-like cells. Plasmacytoid apoptotic bodies are another important feature. A rim of CD4+Lymphocites always surrounds the base of the lesion. Blastic cells showing EBV positivity have a B cell phenotype, being CD45+in up to 50% of cases, CD30+and CD15+, CD20+, Oct-2+and PAX-5+, MUM1+but CD10-and bcl-6-. Good BCL-2, associated with a reduced survival in the past, does not seem to have any prognostic role. [76, 77] Therapy Given Table 4 the poor prognosis, old age at onset, frequent relapses, and extracutaneous spread of PCDLBCL, LT, it is often managed as a systemic lymphoma depending on its staging and location, number of skin lesions, and general status of the patient. The EORTC and ISCL consensus recommendations [44] indicate immunochemotherapy with R-CHOP with or without involved-field radiotherapy as the first-line therapy for single, localized, or generalized lesions. The use of local radiotherapy or rituximab as a single agent can be considered in particular cases. In relapsed cases, the use of protocols for relapsed systemic DLBCLs is recommended. Paulli et al. [77] have reported autologous stem cell transplant as standard of care. Oral lenalidomide monotherapy has demonstrated significant clinical activity but is still under evaluation as there are new monoclonal antibodies and tyrosine kinase inhibitors. [77, 107] 
Primary Cutaneous Diffuse Large B-cell Lymphoma, Other

Introduction
The term PCDLBCL, other, encompasses all cases of CBCL with diffuse infiltration composed of large cells not adaptable in the histopathological criteria for DLBCL, LT. It seems a very rare entity, poorly characterized that shares few cytological features with DLBCL-LT, namely, an infiltrate composed of centroblastic roundish cells and a strong BCL-2 positivity. Neoplastic cells express BCL-6 in all cases described MUM-1+ in 67% and FOX-P1 in 50%. In addition, this large cell infiltrate can be admixed with small lymphocytes. Inside the definition of PCDLBL, others are also included cases with different and even rare morphological variants such as anaplastic, plasmablastic, or T-cell/histiocyte-rich B-cell lymphoma, [9, 89] Epstein-Barr virus-positive DLBCL of the elderly, and intravascular lymphoma. [90, 91] Principal entities and their clinical and histopathological features are resumed in Tables 1-4 .
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